NEW YORK (GenomeWeb News) - Invitrogen said yesterday that it has purchased two molecular probe product lines from TEF Labs.
 
The purchase gives Invitrogen TEF Labs' fluo3 and fluo4 product lines and all related intellectual property. Invitrogen's Molecular Probes business will assume the manufacture and sale of fluo 3 and fluo 4.
 
TEF Labs divested the product lines in order to "focus our resources on the development of new products and technologies," said Akwasi Minta, CEO of TEF Labs, in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.

Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.